Technology
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Published
2 years agoon
By
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα
DURHAM, N.C. and BEIJING, China, March 30, 2025 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.
ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine, in combination with elebsiran (BRII-835) in a previous APAC study BRII-179-835-001 (NCT04749368) were enrolled to Cohort 4 of this study and received elebsiran and PEG-IFNα combination treatment. The design of Cohort 4 as part of this study was based on insight from previous studies that a significant proportion of the chronic HBV patients fail to generate a sufficient immune response after receiving multiple doses of BRII-179, and therefore unlikely to have the immune support to achieve sustainable functional cure.
Emerging data from Cohort 4 showed that participants who previously had BRII-179 induced anti-HBs response achieved a substantially higher rate of HBsAg seroclearance than those who did not. At Week 24, more than half of the BRII-179 responders (55.6% [10/18]) achieved HBsAg seroclearance, compared to only 10.0% (1/10) in non-responders. These latest data suggest that BRII-179 can serve as a predictive tool for enriching patients more likely to respond to curative therapies.
Additional data from Cohorts 1-3 of the ENSURE study showed that higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants receiving elebsiran in combination with PEG-IFNα than those receiving PEG-IFNα alone.
“The positive Cohort 4 data from the ENSURE study opens new doors for HBV functional cure,” said Dr. Grace Lai-Hung Wong, Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China. “Previous studies have suggested that BRII-179 may offer a unique opportunity to identify CHB patients who are able to elicit the necessary HBsAg antibody response. I believe these new findings provide clear evidence supporting such value proposition and further substantiate the role of BRII-179 in shaping future combination therapies.”
“We are encouraged that the Cohort 4 from the ENSURE study continue to support our enrichment strategy in developing a functional cure for chronic HBV in target populations,” said David Margolis, MD, Chief Medical Officer of Brii Bio. “The results underscore the potential of BRII-179 in identifying patients who are more likely to respond to regimens aimed at functional cure, thereby enhancing functional cure rates in the target population while reducing exposure to costly therapies for those with a lower probability of cure. We are committed to advancing BRII-179 in combination with various modalities through our ongoing studies and collaborations with strategic partners, aiming to deliver higher functional cure rates to 254 million patients worldwide living with chronic HBV infection.”
Abstract Number: OP0335
Presentation Title: Responders to Prior BRII-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFNα in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study
Presenter: Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China
Among the 28 of the 31 participants enrolled in Cohort 4 with baseline HBsAg ≥ 100 IU/mL being analyzed, 18 participants with peak anti-HBs ≥ 10 IU/L induced by prior BRII-179 treatment were defined as BRII-179 responders and 10 participants with peak anti-HBs < 10 IU/L were defined as non-responders.At Week 24 of treatment with elebsiran + PEG-IFNα, 39.3% (11/28) of the Cohort 4 participants achieved HBsAg seroclearance.The rate of HBsAg seroclearance at Week 24 in the BRII-179 responders was 55.6% (10/18), notably higher compared to the non-responders at 10% (1/10).Responders to prior BRII-179 treatment appeared to achieve a faster HBsAg seroclearance compared to BRII-179 naïve participants receiving elebsiran + PEG-IFNα as previously reported.Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Treatment with elebsiran + PEG-IFNα is ongoing for 48 weeks.
Abstract Number: LB0009
Presentation Title: Higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants with chronic HBV infection receiving elebsiran (BRII-835) and pegylated interferon alfa-2a (PEG-IFNα) compared to PEG-IFNα alone: Week 48 results from ongoing ENSURE study
Presenter: Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China
The rates of HBsAg seroclearance at EOT in elebsiran 200 mg + PEG-IFNα and elebsiran 100 mg + PEG-IFNα cohorts were 26.3% (5/19) and 33.3% (6/18), respectively, notably higher compared to PEG-IFNα alone cohort (5.6%) in participants with baseline HBsAg levels 100-3,000 IU/mL.Greater HBsAg reductions at EOT were observed in elebsiran + PEG-IFNα combination cohorts (mean [SE]: -2.47 [0.28] or -3.01 [0.28] log10 IU/mL in elebsiran 200 mg or 100 mg, respectively) than in PEG-IFNα cohort (-1.02 [0.30] log10 IU/mL).Elebsiran in combination with PEG-IFNα at both 200 mg and 100 mg doses achieved similar HBsAg reductions and seroclearance rates. Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Post-treatment follow-up is ongoing and will continue for 24 weeks after discontinuation of treatment.
As part of Brii Bio’s unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFNα in studies led by Brii Bio and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology. Key data readouts will be shared in the coming months at the scientific conferences throughout 2025.
About Hepatitis B
Hepatitis B virus (HBV) infection is one of the world’s most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2]
About BRII-179
BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration (the “NMPA”) granted BRII-179 Breakthrough Therapy Designation.
About Elebsiran (BRII-835, VIR-2218)
Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020.
About Brii Bio
Brii Biosciences Limited (“Brii Bio“, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.
[1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240091672
[2] World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.
View original content to download multimedia:https://www.prnewswire.com/news-releases/brii-bio-unveils-new-data-from-its-ongoing-phase-2-ensure-study-at-apasl-2025-showcasing-brii-179s-unique-potential-to-prime-and-boost-higher-hbsag-loss-through-target-patient-identification-302415033.html
SOURCE Brii Biosciences Limited
You may like
Technology
FF EAI Robotics Ecosystem Inc. Announces Details for Its Listing Ceremony and Nasdaq Investor Day, Taking Place on Monday, Oct. 26, at Nasdaq’s MarketSite in NYC
Published
47 minutes agoon
October 21, 2026By
FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) will hold its official listing ceremony to mark the Company’s name and ticker change, and first Investor Day at the Nasdaq Tower on Monday, Oct. 26. Subject to completion of the transaction, FFR management will provide 2026 full year guidance, share details on FFR’s future strategy and business plan.A video recap of the event will be available at 4:30 p.m. ET on Oct. 26 at www.ff.com
LOS ANGELES, Oct. 20, 2026 /PRNewswire/ — FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) (“FFR” or the “Company”), a U.S.-based Embodied AI (EAI) robotics company, today announced details for its Nasdaq listing ceremony and first Investor Day, to be held on Oct. 26 at the Nasdaq Tower in NYC. Subject to completion of the transaction, FFR management will provide 2026 full year guidance, share further details on FFR’s future strategy and business plans at this event and will be available to speak with attending investors onsite. A video recap of the event will be available beginning at 4:30 p.m. ET at www.ff.com.
FFR and FFAI recently signed definitive agreements for FFR to acquire FFAI’s robotics assets and business in an all-stock transaction at an approximate $200 million valuation. FFR will issue shares at $2.246 per share, representing an approximately 50% premium to FFR’s closing price on the date the agreements were signed. Upon closing, FFR will become the No. 1 U.S.-listed pure-play “Four-Core Full-Stack AI” humanoid and bionic EAI robotics ecosystem company.
Note: Event materials will be available on the FF IR website at https://investors.ff.com/events-and-presentations
About FF EAI Robotics Ecosystem Inc.
FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) (renamed from AIxCrypto Holdings, Inc. and AIXC, effective September 30, 2026) is a U.S.-based Embodied AI (EAI) robotics company that is in the process of acquiring the FF EAI Robotics business. Upon completion of the acquisition, the Company will focus on the research and development, manufacturing, commercialization, and deployment of intelligent robotic technologies, products, and industry solutions.
The Company is committed to building a “Four-Core Full-Stack” AI ecosystem covering the full lifecycle of robotics, consisting of EAI Brain & Developer Platform, EAI Devices, Industry Productivity Solutions, and EAI Data Factory. Guided by the technology and product philosophy of “One Brain, Multi-forms, Multi-capabilities,” the Company aims to empower humanoid, biomimetic, and other robotic form factors through a unified EAI Brain, while continuously expanding their multi-task and multi-scenario capabilities. The ecosystem is designed to support the full robotics lifecycle, including R&D, deployment, data collection and training, operations, and commercial applications.
The FF EAI Robotics business has already achieved commercial deliveries of humanoid and biomimetic robotic products. Through its multi-form-factor robotic products, EAI technology platform, closed-loop data capabilities, and industry solutions, the business continues to advance the scaled adoption of robotics across real-world applications. The Company also operates RoboShare, a robot-sharing and services platform designed to connect robotic assets, service capabilities, customer demand, and ecosystem partners, further strengthening its robotics commercialization and service ecosystem.
For more information, visit www.ff.com.
ABOUT FARADAY FUTURE
Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a “Four-Core Full-Stack AI” ecosystem of EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and EAI Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/
FFR Forward-Looking Statements
This communication, including any presentation, press release, investor materials or other document of which it forms a part (this “Communication”), contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws, regarding FF EAI Robotics Ecosystem Inc. (“FFR,” the “Company,” “us,” “our,” or “we”) and our industry. All statements, whether written or oral, other than statements of historical fact, including any financial projections and any statements regarding future events, our strategy, our transition to robotics operations, our plans for RoboShare, our digital asset disposition plans, the proposed acquisition of the FF EAI Robotics business, the projections referenced in this communication, our name and ticker change, any related financing, and the anticipated benefits and timing of the foregoing, our objectives, expectations, or anticipated actions or results, are forward-looking statements. You can often identify forward-looking statements by words such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely,” or “continue,” or the negative of these terms or other similar expressions; the absence of these words does not mean a statement is not forward-looking. These statements reflect our current expectations and projections about future events as of the date of this Communication and are necessarily based on estimates and assumptions that, while considered reasonable by management, are inherently uncertain. FFR can give no assurance that such forward-looking statements or financial projections will prove to be correct.
Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of numerous risks and uncertainties, both general and specific, including, but not limited to:
The proposed acquisition transaction and PIPE. The definitive agreements may be terminated in accordance with their terms, and the proposed transactions may not be completed on the terms described or at all; the conditions to closing, including the completion of FFAI’s internal restructuring of the robotics business, the execution of key employee agreements and other customary conditions, and the parties’ ability to satisfy them; the risk that the stockholder approval required under Nasdaq listing rules for the conversion of the preferred stock issued as consideration is not obtained or is delayed, and the effect of the conversion restrictions and the information statement process on the timing of conversion; the timing of the transaction and the costs of pursuing it; the issuance of a substantial number of shares as consideration and the resulting dilution to existing stockholders; the fact that the counterparty is our controlling stockholder, that it will hold a substantial majority of our outstanding shares following closing, that certain members of management serve both companies, and the conflicts of interest inherent in the transaction; the risk that the agreed valuations do not reflect the market value of our shares or of the acquired business; our dependence on the counterparty for transition, supply and support following any closing; the scope and enforceability of the non-competition and governance arrangements; the consequences of the transaction under Nasdaq listing rules, including the possibility that Nasdaq determines that the transaction requires us to satisfy initial listing requirements in connection with a business combination, change of control or change in the nature of our business; the risk that the PIPE financing, on which the transaction is not conditioned, is not completed on the anticipated terms or at all; the risk of litigation relating to the transaction; our ability to integrate and operate the acquired business; and the risk that the acquired business performs differently than anticipated.
Projections. The projections referenced in this communication were prepared by FFAI management for the FF EAI Robotics business on a standalone basis and do not reflect our existing business, transaction-related expenses or the combined company. We have not independently verified them or adopted them as guidance. They were not prepared with a view toward public disclosure or toward compliance with the published guidelines of the Securities and Exchange Commission or the American Institute of Certified Public Accountants regarding prospective financial information, and no independent registered public accounting firm has examined, compiled or performed any procedures with respect to them, and none expresses an opinion or any other form of assurance with respect to them. The projections reflect estimates and assumptions that are inherently uncertain and subject to change, including through due diligence and the review of our special committee and its financial advisor. Actual results are likely to differ, and may differ materially.
Liquidity, capital and going concern. Our limited cash and liquidity position and our history of operating losses and negative operating cash flow; substantial doubt regarding our ability to continue as a going concern, as described in our periodic reports; our need to obtain additional financing on acceptable terms or at all, and the substantial dilution to existing stockholders that additional financing may cause, including any financing completed in connection with the proposed transaction, which may not be completed or may be on less favorable terms than anticipated; our ability to fund operations pending and following the disposition of our digital asset positions; and our ability to satisfy the continued listing requirements of The Nasdaq Stock Market, including stockholders’ equity, minimum bid price and other applicable standards.
Our strategic transition and the disposition of digital assets. Risks associated with a fundamental shift in our business strategy and the redeployment of resources from a digital asset treasury strategy to robotics operations; our ability to execute the disposition of our digital asset positions in an orderly manner and on acceptable terms; the risk that amounts realized on disposition are materially less than carrying value as a result of price volatility, market depth, execution timing, custody or transfer constraints, or other limitations; tax, accounting and regulatory consequences of the dispositions; the continued volatility and regulatory uncertainty associated with digital assets and cryptocurrencies during the wind-down period; the concentration of a substantial portion of our assets in a single equity investment, including an investment in a related party, and the illiquidity, valuation uncertainty, holding-period and transfer restrictions associated with that investment; and risks arising from our relationships and agreements with related parties and significant stockholders.
Our robotics operations business. Our limited operating history in robotics operations and commercialization and the absence of a meaningful revenue history; the early stage of RoboShare and the risk that customer demand, repeat demand, pricing, utilization or unit economics do not develop as anticipated; our dependence on a small number of customers, on a single initial geographic market, and on individual events or engagements, and the risk that the loss of, or a change in the terms of, any such relationship has a disproportionate effect; our dependence on third-party robot owners, operators, suppliers, original equipment manufacturers and local partners, and on their willingness to make robots available on our platform; risks relating to the availability, cost, quality, maintenance, transport, insurance and technological obsolescence of robots and related equipment, and to supply chains, tariffs and trade measures affecting them; and our ability to expand into additional markets and to attract and retain participants on both sides of our marketplace.
Operations, safety and liability. Risks of property damage, personal injury or death arising from the operation of humanoid robots, quadrupeds and other autonomous or semi-autonomous machines in proximity to performers, employees, guests and the public, including at live events and in uncontrolled environments; product liability, premises liability, negligence and related claims and the adequacy, scope, availability and cost of our insurance coverage and of contractual indemnities from customers, owners and suppliers; the allocation of responsibility among us, robot owners, venues, event producers and customers; permitting, licensing, occupational safety and event-specific regulatory requirements; and the reputational consequences of any safety incident.
Technology, data and intellectual property. Systems, network, telecommunications or service disruptions, failures, defects or cyber-attacks; the performance, reliability and autonomy limitations of robotic systems and of the software, models and networks that support them; our collection, use, storage, transmission and protection of personal information, including images and any biometric or biometric-adjacent data captured in the course of robot deployments, and evolving privacy, biometric and artificial intelligence laws and regulations across the jurisdictions in which we operate or intend to operate; our ability to obtain, maintain, protect and enforce our intellectual property rights and to defend against third-party claims of infringement or misappropriation; and our reliance on third-party technology, platforms and licenses.
Legal, regulatory and general. The regulated industries and jurisdictions in which we operate; current or future laws or regulations and new interpretations of existing laws or regulations, including those applicable to digital assets, robotics, autonomous systems, consumer protection, advertising and endorsements; the risk that our marketplace arrangements, or the manner in which they are described, are characterized differently than we intend by regulators or courts; the failure of counterparties to perform their contractual obligations; litigation, regulatory inquiries, investigations and enforcement actions, and their costs and outcomes; business, economic, market and capital-market conditions; competition in our industry; changes in market demand for, and the pricing of, our products and services; our ability to define, design and release new products and services in a timely manner that meet customer needs; our ability to attract, retain and motivate qualified personnel, including key management; our ability to manage our growth and our transition; and our ability to maintain effective internal control over financial reporting and disclosure controls and procedures.
This list of factors is not exhaustive. Additional risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Reports on Form 10-Q, and our subsequent filings, which are available on the SEC’s website at www.sec.gov. Investors are urged to review the liquidity, capital resources and going concern disclosures contained in those reports.
The forward-looking statements in this Communication speak only as of the date hereof. Except as required by law, neither FFR nor any other person undertakes any obligation to update or revise any forward-looking statement or financial projection set out herein, whether as a result of new information, future events or otherwise. This Communication is provided for informational purposes only, does not constitute an offer to sell or the solicitation of an offer to buy any security, and does not constitute investment, tax or legal advice or any investment recommendation, and does not take into account the investment objectives or financial situation of any person. FFR reserves the right to amend or replace the information contained herein, in whole or in part, at any time, and undertakes no obligation to notify any recipient thereof. Readers are cautioned not to place undue reliance on these forward-looking statements. This caution is made under, and these forward-looking statements are intended to be covered by, the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.
FFAI FORWARD LOOKING STATEMENTS
Important factors that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible debt investors to fund the Company; demand for the Company’s robotics products; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s reliance on Chinese OEMs for all of its robotics products; the possibility of the federal government banning imports of Chinese robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; the ability of the Company to close its transaction with FF EAI Robotics Ecosystem Inc. (FFR) for the sale of its robotics business; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s ability to execute on its plans to enter the robotaxi and cybercab industries; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings; the volatility of the Company’s stock price; the ability of the Company to maintain its stock price above $1.00; and the ability of the Company to maintain compliance with Nasdaq regulations for continued listing. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026; the quarter ended March 31, 2026, filed with the SEC on May 14, 2026; and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ff-eai-robotics-ecosystem-inc-announces-details-for-its-listing-ceremony-and-nasdaq-investor-day-taking-place-on-monday-oct-26-at-nasdaqs-marketsite-in-nyc-302914833.html
SOURCE FF EAI Robotics Ecosystem Inc.
Technology
Lovense Launches Glint, a Touch-Responsive Butt Plug That Syncs Anal Stimulation with a Partner’s Thrust During Intercourse
Published
47 minutes agoon
October 21, 2026By
For vibrator-loving couples, Glint offers something genuinely new: vibration driven by a partner’s touch.
SINGAPORE, Oct. 20, 2026 /PRNewswire/ — In the middle of sex, reaching for a phone to adjust a partner’s toy can interrupt the very connection the toy is meant to create.
Lovense today announced Glint, a touch-responsive butt plug for couples, designed to enhance intercourse by synchronizing anal stimulation with a partner’s thrust for a more intense, connected dual penetration experience. Its external base responds to a partner’s thrust as well as to touch, translating that contact into responsive anal stimulation in real time.
Glint allows couples to shape the experience through the movement and touch they are already sharing—not through a phone screen. Glint is not simply removing the phone from the experience. It changes what controls the experience: physical touch, contact and movement become the real-time input.
The numbers behind the pause
In a nationally representative U.S. study published by researchers at Indiana University[1], 43.8% of heterosexual men reported having used a vibrator. Among male vibrator users, approximately 94% had used one during partnered sexual activity and 82% during intercourse. The research suggests that vibrators are already part of partnered sex. The next question is not whether couples use them, but how physical interaction can become part of the control.
Grand View Research projects the global sextech market to reach USD 107.85 billion by 2030[2,3], growing at 16.77% annually—nearly twice the projected growth rate of the sex toys market, which is expected to reach USD 62.7 billion at a CAGR of 8.69%. Many of these devices now connect to apps and to other devices.
What makes Glint different
Glint is worn anally. The base stays outside the body and carries a touch sensor that reads how much skin is on it, at what angle and for how long, then moves the vibration across five intensity levels. A light touch can produce a lighter response, while broader or firmer contact can produce a stronger response, depending on the user’s sensitivity setting.
Users set their sensitivity and choose from three response modes in the Lovense Remote app:
Pulse, for rhythmic touch-based feedback;Sustain, for continuous vibration while contact continues;Crescendo, for vibration that builds as contact is maintained.
Glint is 0.84 inches (21.5 mm) across and weighs 55 grams. The small size keeps it comfortable to wear and approachable for people new to anal play. Its compact anal form factor is designed to stay out of the way during intercourse. It runs up to 7,500 vibrations per minute, lasts 95 to 178 minutes on a charge depending on level, charges in about an hour and is IPX7 waterproof. Through Toy Sync, its base can also control other Lovense devices.
Three ways couples will use it
Thrust-synced intercourse. During intercourse, each thrust against the external base is synchronized with anal stimulation in real time. The stimulation follows the couple’s rhythm rather than a preset pattern. With Glint in place, dual penetration feels fuller and more intense.
Touch-led foreplay. One partner wears Glint while the other explores the external base with a fingertip or hand. The wearer feels the response change as contact changes. The wearer can choose whether Touch Response is active and set the sensitivity before play begins.
Two toys, one movement. One partner wears Glint while the other wears a compatible Lovense device, such as Edge 2, Lush 4 or Gush 2 Motion. When the toys are paired through Toy Sync, physical contact with Glint can trigger responsive feedback in both devices, allowing the couple’s movement to shape the shared experience in real time. For example, one partner may wear Glint while the other wears Edge 2, Lovense’s prostate massager, allowing both partners to feel stimulation shaped by the same thrust. Either partner can wear Glint. The wearer remains in control, while the couple creates the rhythm together.
For couples in different locations, Lovense Remote continues to provide long-distance control.
For in-person use, Glint includes Touch Records, which is optional and turned off by default. If enabled, Touch Records lets users review selected interaction data after a session.
The oldest interface
“The simplest thing two people do during sex is touch each other,” said Dan Liu, CEO of Lovense. “With Glint, we wanted to explore what happens when touch becomes a new control layer between two people—so the couple can stay inside the interaction rather than reaching for a screen.”
Since 2010, Lovense has built an ecosystem that turns signals from apps, games and live streams into feedback on connected devices. Glint adds physical touch and movement as another way for signals to reach the body. The app is still there for setup and for partners in different cities; during sex, the couple can leave it on the nightstand.
Availability
Glint launches worldwide on October 20, 2026 and will be available at lovense.com.
About Lovense
Lovense is a connected intimacy technology company founded in 2010. Its ecosystem combines smart intimate devices, the Lovense Remote app, creator and live-streaming tools, platform integrations and developer APIs to help individuals and couples create more connected experiences across distance, content and everyday intimacy.
Reference:
1.Reece M, Herbenick D, et al. Vibrator Use Among Heterosexual Men Varies by Partnership Status. Journal of Sex & Marital Therapy, 2010, 36(5): 389–407.
https://doi.org/10.1080/0092623X.2010.510774
2.Grand View Research, SexTech Market Size To Reach $107.85 Billion By 2030. https://www.grandviewresearch.com/press-release/global-sextech-market
3.Grand View Research, Sex Toys Market Size To Reach $62.7 Billion By 2030. https://www.grandviewresearch.com/press-release/global-sex-toys-market
View original content to download multimedia:https://www.prnewswire.com/news-releases/lovense-launches-glint-a-touch-responsive-butt-plug-that-syncs-anal-stimulation-with-a-partners-thrust-during-intercourse-302914858.html
SOURCE Lovense
Technology
Kontron Launches Two New KBox F-Series Industrial Computers To Bring Greater Flexibility and Scalability to Industrial Edge Computing
Published
2 hours agoon
October 21, 2026By
TAIPEI, Oct. 21, 2026 /PRNewswire/ — Kontron, a leading global provider of IoT/Embedded Computing Technology (ECT), expands its KBox F-Series with the KBox F-203-RPS and KBox F-204-RPS, two compact industrial computers designed to address diverse requirements in intelligent Industry 4.0, edge computing and industrial IoT applications.
Both systems are powered by 12th, 13th or 14th Gen Intel® Core™ i9/i7/i5/i3 S-Series socket-type processors with a TDP of up to 65 W and support up to 96 GB DDR5 memory, providing a scalable computing foundation for demanding industrial applications requiring flexible performance configuration and long-term deployment.
The KBox F-203-RPS offers two LAN configurations with either two or four GbE ports, allowing customers to select the connectivity level that best fits their applications. The dual-LAN configuration provides an efficient solution for general industrial computing, equipment control and edge applications, while the four-LAN configuration offers additional network connectivity for applications involving multiple devices or network segments, such as machine vision, industrial automation and IoT gateways.
For applications requiring greater system expandability, the KBox F-204-RPS provides one PCIe x16 or two PCIe x8 expansion slots, offering the flexibility to integrate graphics, networking, AI acceleration or other add-on cards according to specific application requirements. With support for up to four 2.5-inch SATA HDDs/SSDs, it also provides extensive storage scalability for data-intensive workloads. These capabilities make the KBox F-204-RPS particularly suitable for industrial edge computing, machine vision, video processing and applications requiring additional functionality or large local data storage.
Together, the KBox F-203-RPS and KBox F-204-RPS enable customers to select the configuration that best matches their requirements, from a slimmer, network-focused industrial computer to a highly expandable edge computing platform.
To learn more about KBox F-203-RPS and KBox F-204-RPS, refer to https://www.kontron.com/en/products/kbox-f-203-rps/p301099 and https://www.kontron.com/en/products/kbox-f-204-rps/p311867.
About Kontron
At Kontron, we champion IoT and Industry 4.0, by creating secure, state-of-the-art solutions that span hardware, software and services. Our approach speeds market entry, reduces the cost of ownership, and offers longevity, ensuring our role as your trusted partner in the integration of smart technologies. For more information, please visit www.kontron.com, dial +886-2-2799-2789 or email SalesAsia@kontron.com.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/kontron-launches-two-new-kbox-f-series-industrial-computers-to-bring-greater-flexibility-and-scalability-to-industrial-edge-computing-302909761.html
SOURCE Kontron
FF EAI Robotics Ecosystem Inc. Announces Details for Its Listing Ceremony and Nasdaq Investor Day, Taking Place on Monday, Oct. 26, at Nasdaq’s MarketSite in NYC
Lovense Launches Glint, a Touch-Responsive Butt Plug That Syncs Anal Stimulation with a Partner’s Thrust During Intercourse
Kontron Launches Two New KBox F-Series Industrial Computers To Bring Greater Flexibility and Scalability to Industrial Edge Computing
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market5 days agoOpenAI model helped itself to testnet crypto, then kept quiet about it
-
Technology5 days agoFF EAI Robotics (FFR) and FF Jointly Launch FF Nova, First Embodied AI Humanoid Robot Priced Below $2,500 in U.S., FF Nova Mini, Physical AI Spark Program Curriculum, Nova Reinforcement Learning Developer Program and Developer Community Recruitment
-
Technology4 days agoJinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency
-
Technology4 days agoHighland and Bath Counties, Virginia Go Live on a Shared Caliber Hosted CAD Environment
-
Coin Market4 days agoBitcoin price steadies around $82K after Fed’s Warsh avoids rate-hike hints
-
Technology5 days agoFrost & Sullivan: Netradyne Receives the 2026 Global Commercial Vehicle Video Telematics Product Leadership Recognition for Excellence in AI-Driven Fleet Safety and Operational Intelligence
-
Near Videos4 days agoWhat if you could build a skyscraper with one prompt?
-
Technology5 days ago
/R E P E A T — Media Advisory – Minister Hodgson to deliver remarks and participate in fireside chat/
